Tirz is an investigational peptide compound characterized by its dual agonist activity at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It has been structurally optimized to improve pharmacokinetic stability, incorporating molecular modifications that extend its duration of activity. These design features support sustained receptor engagement and have made tirz a subject of interest in metabolic and endocrinology research settings.
 
Tirz is provided for laboratory research purposes only and is not approved for human use.